Boltz PBC launched with a $28 million seed round led by Amplify, a16z and Zetta to commercialize open-source AI models for molecular design. Founders from MIT’s CSAIL positioned Boltz as a platform company — not a single-drug shop — offering Boltz Lab and agents for small-molecule and protein design to accelerate discovery across academia and biotech. Investors emphasized tool adoption and broad access as the company’s core strategy.